VAUGHAN, Ontario--(BUSINESS WIRE)-- Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from a Phase 2 study evaluating BL1332, a first-in-class topical TRPV1 antagonist, in patients experiencing pain following photorefractive keratectomy (PRK) surgery.

“What stands out from this study is the consistency of the findings,” said Yehia Hashad, MD, executive vice president, R&D and chief medical officer, Bausch + Lomb. “Both dose groups showed numerically greater pain relief than vehicle across all the pain measures we evaluated, more patients achieved complete pain relief following surgery and we observed evidence of faster corneal healing. These findings help define the clinical profile of BL1332 and will inform our discussions with the FDA on next steps, including potential Phase 3 planning.”

Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain

Business Wire